(Credit: Nicoleta Ionescu/Shutterstock)
Not Everyone’s Brain Suffers Equally From Poor Sleep, and Your DNA May Be Why
In A Nutshell
- Researchers found that variations in a gene called AQP4, which helps the brain flush waste during sleep, were linked to differences in brain size, tissue loss, and thinking ability in older adults at elevated Alzheimer’s risk.
- Whether poor sleep was associated with brain tissue loss depended on which version of the AQP4 gene a person carried, suggesting sleep’s impact on the brain may not be the same for everyone.
- Sleep duration, time to fall asleep, and overall sleep quality each appeared to interact with specific AQP4 variants to influence brain aging outcomes.
- Because sleep is something people can change, researchers see it as a potential target for future risk-reduction strategies, though no causal link has been established.
Most people assume that poor sleep is bad for the brain, full stop. But a new study complicates that picture in a way that could matter for how scientists think about Alzheimer’s risk and future prevention research. Whether poor sleep is linked to signs of brain aging may depend, at least in part, on which version of a specific gene you inherited.
Researchers studying older adults at elevated risk for Alzheimer’s found that genetic variations in a gene called AQP4, which carries instructions for a protein that helps water move through brain tissue during sleep, were linked to differences in brain size, brain tissue loss, and mental sharpness. Crucially, the relationship between sleep and brain health didn’t look the same for everyone. It shifted depending on which version of the gene a person carried.
Published in Alzheimer’s & Dementia, the findings add a new layer to the science of sleep and brain aging. Sleep might not be a one-size-fits-all factor in Alzheimer’s risk, and genetics could help explain why some people’s brains seem more vulnerable to poor sleep than others.
Poor Sleep May Hit Harder for People With Certain AQP4 Gene Variants
During sleep, the brain runs what scientists describe as a drainage system, a network of fluid pathways that flushes out harmful waste products, including amyloid beta, the protein that builds up in Alzheimer’s disease. AQP4 makes a protein that acts as a gatekeeper for this system, helping fluid move through brain tissue. When this system doesn’t work well, waste accumulates, and over decades, that buildup is believed to contribute to brain changes seen in Alzheimer’s.
351 At-Risk Adults, 13 Gene Variants, and a Sleep Survey
Data came from the Australian Imaging, Biomarkers and Lifestyle study, a long-running project tracking older adults with detailed data on brain health, genetics, and daily habits.
For this analysis, the team focused on 351 cognitively unimpaired participants who already had evidence of amyloid beta building up in their brains, placing them at elevated Alzheimer’s risk before any symptoms appear. The average age was about 75, and slightly more than half were male.
Sleep habits were measured using the Pittsburgh Sleep Quality Index, a standard questionnaire capturing sleep duration, time to fall asleep, waking frequency, and overall quality. All data were self-reported rather than monitored in a lab.
Brain scans tracked amyloid beta levels and brain region sizes over time. Participants also completed memory and thinking tests. On the genetics side, the team examined 13 specific variations across the AQP4 gene.
Shorter Sleep Tied to Faster Brain Tissue Loss in Specific AQP4 Carriers
Genetic analysis turned up two types of findings: direct associations between AQP4 variants and brain health, and cases where sleep appeared to amplify or suppress those effects. One variant, rs162007, was directly linked to better performance on a composite thinking test regardless of sleep habits, though its biological meaning still needs to be worked out.
Sleep-gene interactions told a more layered story. Among people carrying one version of a variant called rs151245, shorter sleep duration was associated with faster brain tissue loss in the outer layer of the brain. For those with a different version, no such relationship appeared. In other words, the same number of hours of sleep could mean something very different depending on genetic makeup.
A similar pattern emerged for the brain’s fluid-filled interior spaces. Carriers of a variant called rs7240333 who took longer to fall asleep showed larger fluid spaces. Another variant, rs2339214, was linked to faster expansion of those spaces in people with worse overall sleep quality.
On the cognitive side, two variants showed a more puzzling pattern: among people who inherited two copies of the less common version, greater sleep disturbances were linked to less cognitive decline. Researchers flag this cannot be interpreted as a protective effect, and the authors note that AQP4 variant effects appear highly context-dependent with the underlying mechanism still unclear.
No strong associations turned up between AQP4 variants and amyloid beta levels in the brain itself. Researchers suggest any genetic effects on amyloid buildup may have played out earlier in life, given that participants were selected specifically because they already had amyloid accumulation.
Sleep Is Modifiable, but Researchers Stop Short of Calling It a Fix
Sleep is something people can potentially change, unlike the genes they were born with, and that distinction matters. Researchers are careful to note their findings don’t prove improving sleep will protect the brain. This study shows associations, not causes, and randomized trials would be needed before any such conclusion is drawn.
Alzheimer’s builds over decades, shaped by genetics, lifestyle, and the biology of the sleeping brain. For at least some people, which AQP4 variant they carry may quietly be tied to how much damage a run of bad nights leaves behind, and whether that connection can be broken is a question researchers are pressing hard to answer.
Disclaimer: This study examined associations between genetic variants, sleep habits, and brain health markers in older adults at elevated Alzheimer’s risk. It does not establish cause and effect, and the findings should not be interpreted as medical advice. Consult a qualified healthcare provider with any questions about Alzheimer’s risk or sleep health.
Paper Notes
Study Limitations
The study relied on self-reported sleep data collected through a questionnaire, which is subject to recall bias and personal interpretation. While the researchers found that participants’ sleep patterns appeared relatively stable over the course of the study, sleep habits can change over time in ways that the questionnaire may not have captured. The longitudinal brain volume analyses were conducted in a subset of 108 participants, a relatively modest sample size that may have reduced the ability to detect smaller genetic or interaction effects. The study focused exclusively on older adults who were already accumulating amyloid beta in their brains but had no symptoms, and the cohort was predominantly Caucasian and highly educated, limiting the generalizability of findings. The researchers also acknowledge the possibility of collider bias: because participants were selected based on amyloid accumulation, and because AQP4 variants and sleep may both influence amyloid buildup, the selection process could have introduced statistical distortions. Sensitivity analyses in broader, unselected populations would be needed to address this.
Funding and Disclosures
The study received financial support from the Alzheimer’s Association (USA), the Alzheimer’s Drug Discovery Foundation, an anonymous foundation, the Science and Industry Endowment Fund, the Dementia Collaborative Research Centers, the Victorian Government’s Operational Infrastructure Support program, the Australian Alzheimer’s Research Foundation (now Alzheimer’s Research Australia), the National Health and Medical Research Council (NHMRC), and the Yulgilbar Foundation. NHMRC grants GNT1161706 and GNT2001320 supported the genetic data component. Stephanie R. Rainey-Smith is supported by an NHMRC Investigator Grant (GNT1197315). Several authors disclosed potential conflicts of interest: Victor L. Villemagne has served as a consultant or paid speaker for Eli Lilly, Life Molecular Imaging, ACE Barcelona, and IXICO. Paul Maruff is a full-time employee of Cogstate Ltd. Christopher C. Rowe has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare, and AstraZeneca; has received speaker honoraria from Bayer Pharma and GE Healthcare; and has received research support from Bayer Pharma, GE Healthcare, Piramal Life Sciences, and Avid Radiopharmaceuticals. The remaining authors reported no disclosures.
Publication Details
Authors: Tenielle Porter, Ayeisha Milligan Armstrong, Eleanor K. O’Brien, Vincent Doré, Pierrick Bourgeat, Mitchell Turner, Paul Maruff, Christopher C. Rowe, Belinda M. Brown, Victor L. Villemagne, Stephanie R. Rainey-Smith, Simon M. Laws, and the AIBL Research Group. Porter and Milligan Armstrong are listed as joint first authors; Rainey-Smith and Laws are listed as joint last authors. Journal: Alzheimer’s & Dementia Paper Title: “Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer’s disease phenotypes” DOI: 10.1002/alz.71516 Year: 2026
